Yu Qiyao, Li Jie, Mao Wenjie, Li Zheng, Li Xuan, Li Bin
Department of Plastic Surgery BOE Hospital Chengdu China.
Department of Thoracic Surgery Second Hospital of Lanzhou University, Second Clinical Medical College of Lanzhou University China.
Health Sci Rep. 2024 Nov 25;7(11):e70178. doi: 10.1002/hsr2.70178. eCollection 2024 Nov.
There are still no useful biomarkers for the prognosis of esophageal squamous cell carcinoma (ESCC). In the prognosis of some kinds of cancer, soluble programmed death 1 (sPD-1) and programmed death ligand 1 (sPD-L1) have demonstrated statistical significance, but the prognostic value of serum sPD-L1 and sPD-1 remains unclear in ESCC.
Here, a meta-analysis was performed to estimate the prognostic value of sPD-L1 and sPD-1 in ESCC. To obtain eligible studies, we searched mainstream databases (PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and CNKI), and the survival data including hazard ratios (HR) and its 95% confidence intervals (95% CI) from included literature were extracted.
Six articles were included, including 645 patients with ESCC. The statistical result of this meta-analysis indicated that serum sPD-1 had no significant correlation with overall survival (OS) of patients with ESCC ( > 0.05). Patients with ESCC with high concentrations of serum sPD-L1 demonstrated a significantly poor prognosis (HR = 1.73, 95% CI: 1.42-2.11, < 0.001).
Higher levels of serum sPD-L1 may predict poor OS in ESCC patients, which may be a promising and credible prognostic biomarker for esophageal cancer.
目前仍没有可用于预测食管鳞状细胞癌（ESCC）预后的有效生物标志物。在某些癌症的预后评估中，可溶性程序性死亡蛋白1（sPD-1）和程序性死亡配体1（sPD-L1）已显示出统计学意义，但血清sPD-L1和sPD-1在ESCC中的预后价值仍不明确。
在此，我们进行了一项荟萃分析，以评估sPD-L1和sPD-1在ESCC中的预后价值。为获取符合条件的研究，我们检索了主流数据库（PubMed、Cochrane、Embase、Web of Science、万方数据和中国知网），并从纳入文献中提取了包括风险比（HR）及其95%置信区间（95%CI）在内的生存数据。
纳入6篇文章，共645例ESCC患者。该荟萃分析的统计结果表明，血清sPD-1与ESCC患者的总生存期（OS）无显著相关性（>0.05）。血清sPD-L1浓度高的ESCC患者预后明显较差（HR = 1.73，95%CI：1.42 - 2.11，<0.001）。
血清sPD-L1水平较高可能预示ESCC患者的OS较差，这可能是一种有前景且可靠的食管癌预后生物标志物。
